A Indiana overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
38.4% of Indiana adults have obesity, per the CDC's 2024 BRFSS estimate (95% CI 37.3–39.5%, n=11,576) 1. That is across 6,924,275 residents as of July 1, 2024 2.
What decides the cost of treatment here is not the prevalence but a single line of Indiana administrative code, written decades before these drugs existed.
Not covered. Indiana Medicaid does not cover GLP-1 medications for weight loss. State administrative code 405 IAC 5-24-3(b)(1) categorically excludes "anorectics or any agent used to promote weight loss" from the Medicaid pharmacy benefit — a blanket, program-wide exclusion, not a prior-authorization hurdle 3.
GLP-1s (semaglutide, tirzepatide) can still be Medicaid-covered under standard PDL/prior-authorization rules when prescribed for type 2 diabetes — a separate, FDA-approved indication. No IHCP bulletin issued in 2025 or 2026 has announced a change to this exclusion 4.
The citation behind that reading is the Indiana Health Coverage Programs (IHCP) "Pharmacy Services" Provider Reference Module (PROMOD00042, v8.0), published Aug. 12, 2025, Section 2 "Pharmacy Coverage and Reimbursement," quoting 405 IAC 5-24-3(b)(1) 3.
With the weight-loss indication excluded from the Medicaid pharmacy benefit, an Indiana member pursuing GLP-1 treatment for obesity is paying cash.
Astra's price in Indiana is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Indiana price list and no regional discount.
Median household income in Indiana is $71,959 and roughly 7.5% of residents are uninsured (approx., ACS 2024 1-year estimates) 6.
Indiana has 229 federally designated primary-care Health Professional Shortage Areas statewide, 80 of them rural (HRSA, as of Aug. 27, 2026) 5.
With 80 of Indiana's 229 primary-care shortage areas classified rural, many patients face a long drive for an in-person weight-management or endocrinology visit. Telehealth removes that barrier: Astra's clinicians prescribe and monitor GLP-1 treatment by video visit from anywhere in the state.
TODO — not yet verified. Indiana's telehealth prescribing rules are set by the Medical Licensing Board of Indiana; the direct board subpage was not reachable in this review pass, so this page links the verified-live Indiana Professional Licensing Agency professions index instead 7. Indiana-specific prescribing requirements are not asserted here until a follow-up research pass confirms them.
Astra is licensed to treat patients in Indiana and in all 50 states.
Astra treats patients in Indiana through state-licensed physicians.
City-level obesity, coverage, and local access detail for Indiana.
No. Indiana's own Medicaid pharmacy rule, 405 IAC 5-24-3(b)(1), excludes "anorectics or any agent used to promote weight loss" from coverage — a blanket exclusion restated in IHCP's Aug. 12, 2025 Pharmacy Services module. GLP-1s can still be Medicaid-covered when prescribed for type 2 diabetes under normal prior-authorization rules; that's a different indication, not a weight-loss carve-out.
No. Astra charges the same nationwide: $68/mo for semaglutide and $118/mo for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually). There is no Indiana markup and no Indiana discount — the price is identical everywhere Astra serves, including Fort Wayne.
Yes. Astra is licensed to treat patients in all 50 states, including every county in Indiana. That matters here specifically: 80 of Indiana's 229 primary-care shortage areas are rural, so a telehealth option removes a real driving-distance barrier for many Indiana patients.
Yes. Fort Wayne patients can start with Astra online today — see the Fort Wayne GLP-1 page for local specialist-access details alongside the same national pricing described here.
TODO — not yet independently verified. Indiana's telehealth prescribing rules are set by the Medical Licensing Board of Indiana (see source link below); this answer needs a follow-up research pass before publishing rule-specific claims.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.